AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01972490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
Study NCT01972490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
Study NCT02753179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head Impulse Tests
Description: Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
Study NCT02753179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic visual acuity Test (DVAT)
Description: Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
Study NCT02753179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VEMPs & VEMPo
Description: VEMPs \& VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
Study NCT02753179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory
Description: Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
Study NCT02753179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oscillopsia severity questionnaire
Description: Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
Study NCT01966484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
Study NCT01966484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mivacurium
Description: Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
Study NCT02846363 — intervention group
Intervention type: OTHER
Intervention: public awareness campaign
Description: The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~* 3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~* A leaflet on stroke will be created~* 3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~* Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~* A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~* On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently
Study NCT04322292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
Study NCT04222413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metarrestin
Description: Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA
Study NCT02278835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: breathing exercises
Description: 3 sets of 10 repetitions of deep breathing exercises
Study NCT02278835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: incentive spirometry
Description: 3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
Study NCT02278835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent positive pressure breathing
Description: 20 minutes breathing with intermittent positive pressure
Study NCT02278835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure
Description: 20 minutes breathing with continuous positive airway pressure
Study NCT03397251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMDS
Description: The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
Study NCT04244097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
Study NCT04244097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
Study NCT04244097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
Study NCT03548363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gingest powdered extract obtained from Ginger rhizomes
Description: Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate
Study NCT03548363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg/d maltodextrin
Study NCT01851135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological examination and quality of life measures
Study NCT01851135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological examination and quality of life measures
Study NCT01322880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion sessions
Description: Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
Study NCT01322880 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Village Savings and Loans Associations
Description: The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
Study NCT01322880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village Savings and Loans Associations
Description: The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
Study NCT01987765 — intervention group
Intervention type: DRUG
Intervention: Relestat Ophthalmic Solution 0.05%
Description: Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
Study NCT01811758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Specific CBT
Study NCT01811758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CBT
Study NCT04514939 — intervention group
Intervention type: OTHER
Intervention: Elevation of the legs during bed rest
Description: Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
Study NCT01190865 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HP802-247
Description: One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
Study NCT00824291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: 50 mg/day oral tablet for 12 weeks
Study NCT00824291 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: CYP2D6 genotyping at randomization
Study NCT02092363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-54F28, Paclitaxel and Carboplatin
Study NCT00222118 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: labor/birth preparation classes
Description: prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
Study NCT00222118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention
Description: prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
Study NCT00222118 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: no intervention
Study NCT00829790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: 25 mg 5mL oral dose
Study NCT00829790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Monohydrate
Description: 25 mg 5 mL dose
Study NCT00545792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
Study NCT02208128 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Sunitinib, Pazopanib, Bevacizumab, Everolimus...
Description: Clinical standard
Study NCT04369937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (Intensity Modulated Radiotherapy)
Description: Radiation therapy
Study NCT04369937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
Study NCT04369937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy
Study NCT04369937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
Study NCT02561520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP eye drops
Description: Eye drops 4x a day, patients will start this eye drop first.
Study NCT02561520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPP eye drops
Description: Eye drops 4x a day, patients will start this eye drops after PRP.
Study NCT00968812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
Study NCT00968812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
Study NCT00968812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be given orally at the protocol-specified dose for 104 weeks.
Study NCT00968812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be given orally at the protocol-specified dose for 104 weeks.
Study NCT01831362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Study NCT01831362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Attention (FA)
Study NCT01831362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open- Monitoring
Study NCT03003091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Needs-based patient education
Study NCT03003091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional patient education
Study NCT03341182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoroscopically Guided Lumbar Transforaminal Epidural Injections
Description: Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20\~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
Study NCT03341182 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional manner
Description: A portable mirror is located at the side of surgical table and used in this procedure.
Study NCT01001403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat
Description: 0.2 mg/kg as bolus 1 minute before reperfusion
Study NCT01001403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 10 ml of normal saline
Study NCT00857454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: 30 mg to 120 mg administered topically once daily for 60 days
Study NCT03031184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Study NCT03031184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01112254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI±biopsy
Description: A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
Study NCT00211263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Clinical Intervention
Study NCT00211263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mood stabilizer
Study NCT00211263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mood stabilizer
Study NCT00245063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given PO
Study NCT00245063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04077723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Englumafusp alfa
Description: Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
Study NCT04077723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).
Study NCT04077723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III
Study NCT04077723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
Study NCT02670304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: letrozole from the day of oocyte retrieval for 5 days
Study NCT02670304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: aspirin from the day of oocyte retrieval for 5 days
Study NCT00049764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Study NCT00049764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03426046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy
Description: Partial removal of inflamed pulp tissue in cariously exposed teeth
Study NCT03426046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Pulpotomy
Description: Partial removal of inflamed pulp tissue in cariously exposed teeth
Study NCT03426046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulp Capping Agents
Description: Biocompatible materials
Study NCT03426046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulp Capping Agents
Description: Biocompatible materials
Study NCT04387279 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Surveys on medical use patterns and patient's perceptions about COVID-19
Study NCT01597362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopy
Description: Trocar access in laparoscopy
Study NCT01597362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume.